Exane Derivatives’s bluebird bio BLUE Stock Holding History

Exane Derivatives’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Hold	0	–	–	–	755
2022 Q1	–	Hold	0	–	–	–	1011
2021 Q4	–	Hold	0	–	–	–	872
2021 Q3	–	Hold	0	–	–	–	1024
2021 Q2	–	Hold	0	–	–	–	1022
2021 Q1	–	Hold	0	–	–	–	858
2020 Q4	–	Hold	0	–	–	–	791
2020 Q3	–	Hold	0	–	–	–	711
2020 Q2	–	Hold	0	–	–	–	641
2020 Q1	–	Hold	0	–	–	–	653
2019 Q4	–	Hold	0	–	–	–	616
2019 Q3	–	Hold	0	–	–	–	592
2019 Q2	–	Hold	0	–	–	–	584
2019 Q1	–	Sell	-27	Closed	-$47.5K	–	516
2018 Q4	$34.4K	Buy	+27	New	+$41.4K	0.01%	399

Other funds holding BLUE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Exane Derivatives's BLUE Position: Q2 2022 in Review

Exane Derivatives held its bluebird bio (BLUE) position steady in Q2 2022 at 0 shares worth $21. The position accounts for ﹤0.01% of the portfolio, ranked #755.

Exane Derivatives first reported a position in BLUE in Q4 2018 and has held it in 1 quarter since. The position peaked at $34.4K in Q4 2018. 150 funds tracked by Wall St. Rank hold BLUE as of Q2 2022.

Exane Derivatives held 0 shares of bluebird bio worth $21 as of Q2 2022.
Exane Derivatives left its bluebird bio share count unchanged in Q2 2022.
bluebird bio made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #755 holding.
Exane Derivatives first reported a position in bluebird bio in Q4 2018 and has held it in 1 quarter since.
Exane Derivatives's bluebird bio position peaked at $34.4K in Q4 2018.
150 funds tracked by Wall St. Rank held bluebird bio as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.